Identification and functional characterization of an mRNA Cap3 methyltransferase from Acanthamoeba castellani medusavirusi Authors: Tokiaki Takemura, Kazuya Ishige Published: 2026 ABSTRACT Eukaryotic mRNAs possess a characteristic 5′-end structure known as the cap. Cap0 (m7GpppN) is the simplest form, followed by Cap1 and Cap2, which contain additional O-methyl modifications at the 2′-hydroxyl positions of the ribose moieties of the first and second nucleotides, respectively. Higher-order cap structures, such as Cap3 and Cap4, have been identified in kinetoplastids and other organisms. Although the enzymes responsible for these modifications have been inferred through vivo studies, no enzyme with confirmed in vitro activity has been reported to date. In this study, we identified and functionally characterized a novel mRNA-dependent Cap3 methyltransferase from Acanthamoeba castellanii medusavirus, demonstrating in vitro Cap3 activity for the first time. Sequence analysis revealed homology to known cap methyltransferases. Enzyme kinetic analysis demonstrated an adequate Km value, indicating a moderate substrate affinity and suitability for practical applications. Furthermore, Cap3MTase enabled the preparation of novel Cap3-mRNAs, offering a valuable tool for mRNA modification and therapeutic development. The 5′ cap structure of eukaryotic mRNA plays a critical role in stability, nuclear export, and translation initiation (1). This cap structure, called Cap0, is typically composed of a 7-methylguanosine (m7G) linked via a 5′–5′ triphosphate bridge to the first transcribed nucleotide. Cap1 and Cap2 are modified cap structures that feature further 2′-O-methylation of the ribose moieties of the first and second nucleotides, respectively. Cap1 and Cap2 structures are widely found in animals, plants, and viruses (2, 3, 4, 5). In some kinetoplastids, unique additional methylations give rise to Cap3 and Cap4 structures at the 5′ end of spliced leader RNAs, which undergo trans-splicing to form mature mRNAs (6, 7, 8). Zamudio et al. (2006) identified two candidate 2′-O-ribose methyltransferases, TbCom1 (TbMTr2) (accession no. Tb11.02.2500) (9) and TbMTr3 (accession no. Tb09.211.3130) (10), responsible for Cap4 formation in the kinetoplastid Trypanosoma brucei. However, direct biochemical evidence for in vitro Cap3 methylation activity of TbMTr3 remains inconclusive (10). Although recombinant TbMTr3 was shown to bind the methyl donor S-adenosylmethionine (SAM) and exhibit preferential affinity for m7G-capped RNA substrates, the study did not demonstrate Cap3 methylation activity through direct enzymatic assays (10). Instead, the functional assignment of TbMTr3 as a Cap3 methyltransferase was inferred from RNA interference–mediated knockdown experiments, which resulted in accumulation of Cap2 intermediates and reduced Cap4 methylation. These findings suggest a role for TbMTr3 in Cap3 formation, but further in vitro reconstitution of the methylation reaction is required to confirm its catalytic specificity. TbMTr3 shares notable similarities with viral methyltransferases, such as Vaccinia virus VP39, suggesting a possible viral origin for the enzyme through horizontal gene transfer (11, 12, 13). Building on this evolutionary perspective, we investigated viral cap methyltransferases to gain insights into the origins of cap structures in Protozoa and to explore potentially novel enzymatic activities. Acanthamoeba castellanii medusavirus, which infects the protozoan A. castellanii, belongs to the phylum Nucleocytoviricota, a group commonly referred to as giant viruses (14, 15, 16). Unlike many other viruses, A. castellanii medusavirus initiates infection by entering the host nucleus, where it uniquely replicates its viral genome (17). Genomic analyses have revealed that medusavirus encodes several proteins with homology to eukaryotic RNA processing enzymes, including putative cap methyltransferases (14, 18). A prevailing hypothesis suggests that the eukaryotic nucleus may have originated from an ancestral large DNA virus, such as one belonging to the phylum Nucleocytoviricota (19, 20). Given its nuclear replication strategy and evolutionary proximity to eukaryotic systems, we hypothesized that viruses infecting protozoan species—including Amoebazoa and Euglenozoa, which have trans-splicing systems (21)—may retain ancestral enzymes that served as the evolutionary origin of 2′-O-methyltransferases, including Cap3 and Cap4 methyltransferases. In this study, we sought to investigate the functional properties of candidate cap methyltransferases encoded by A. castellanii medusavirus. Through sequence homology analysis, we identified a previously uncharacterized enzyme, which we named Cap3MTase, containing conserved motifs typical of 2′-O-methyltransferases. Through liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis, we demonstrated that Cap3MTase specifically catalyzes sequential methylation of the third nucleotide of mRNA, producing Cap3 structures in vitro. Furthermore, we showed that Cap3MTase exhibits adequate substrate affinity and enables the synthesis of mRNAs that have lower immunogenicity compared with legacy 5′-cap mRNAs, highlighting its potential utility in mRNA engineering and therapeutic development. In light of recent advances in mRNA-based therapeutics (22, 23), this study also sheds light on the potential applications of Cap3MTase in the context of mRNA medicine development. Importantly, this enzyme allows the production of mRNAs containing a newly synthesized cap structure, Cap3-mRNA, which had previously been difficult to synthesize, thereby expanding the scope of functional mRNA design. Results Sequence-based identification of a putative cap methyltransferase in medusavirus The A. castellanii medusavirus genome has been shown to encode several proteins with homology to eukaryotic RNA processing enzymes, including those involved in mRNA cap modification. Given the unique nuclear replication strategy of the virus and its evolutionary proximity to eukaryotic systems, we hypothesized that medusavirus may possess functionally active cap methyltransferases. To explore this possibility, we conducted a comprehensive sequence analysis focusing on conserved domains associated with 2′-O-methyltransferase activity. The predicted 50.3-kDa protein (NCBI No.: YP_010801901.1) was designated Cap3MTase hereafter and exhibited varying extents of homology to known cap methyltransferases, including sequence identities of 29.1% and 31.8% to V. virus VP39 and T. brucei TbCom1/TbMTr2 (9, 12, 13), respectively. This candidate protein contained hallmark features such as the conserved K-D-K-E motif (24, 25, 26), which is typical for 2′-O-methyltransferases and has been identified in the Rossmann fold class of methyltransferase superfamily (27) (Fig. 1). Phylogenetic analysis placed the protein within a distinct viral clade, and structural modeling predicted a Rossmann fold typical of SAM-dependent enzymes (28). In addition to the conserved SAM-binding motif, a Y-Y-E motif composed of aromatic residues and glutamic acid was found in Cap3MTase. This motif was identified as the cap-binding domain by referring to the crystal structure of VP39 (29). Based on these features, we designated the protein as Cap3MTase and proceeded to investigate its biochemical properties.Figure 1Sequence comparison of various cap-specific 2′-O-methyltransferases. Alignment of amino acid sequences of VP39 (Vaccinia virus), TbCom1/TbMTr2 (Trypanosoma brucei), TbMTr3 (Trypanosoma brucei), and Cap3MTase. The red bold residues indicate that the Rossmann fold class of methyltransferases of the RrmJ/fibrillarin superfamily are conserved in all four proteins. The green bold residues indicate that a m7G cap-binding domain “Y-Y-E motif” is conserved in all four proteins. The secondary structure of VP39 is indicated above the aligned sequence. α-helices are depicted as orange bars and β-sheets as blue arrows. m7G, 7-methylguanosine. Sequence comparison of various cap-specific 2′-O-methyltransferases. Alignment of amino acid sequences of VP39 (Vaccinia virus), TbCom1/TbMTr2 (Trypanosoma brucei), TbMTr3 (Trypanosoma brucei), and Cap3MTase. The red bold residues indicate that the Rossmann fold class of methyltransferases of the RrmJ/fibrillarin superfamily are conserved in all four proteins. The green bold residues indicate that a m7G cap-binding domain “Y-Y-E motif” is conserved in all four proteins. The secondary structure of VP39 is indicated above the aligned sequence. α-helices are depicted as orange bars and β-sheets as blue arrows. m7G, 7-methylguanosine. Identification of a novel cap-dependent RNA Cap3 methyltransferase To assess the enzymatic activity of Cap3MTase, we cloned its coding sequence into a bacterial expression vector and expressed the recombinant protein in Escherichia coli. The protein was purified through several steps of chromatography along with Ni–nitrilotriacetic acid affinity chromatography (Fig. 2A). To assess whether Cap3MTase exhibits cap-dependent RNA methyltransferase activity, we synthesized two oligo-mRNA substrates: pppGAAAA and m7GpppGAAAA. Each substrate was incubated with Cap3MTase in the presence of SAM under standard reaction conditions, and the resulting methylation activity was subsequently evaluated through liquid chromatography analysis. When the uncapped substrate pppGAAAA was used, no change in the substrate peak was observed and no reaction product was detected (Fig. 2B). By contrast, incubation with the capped substrate m7GpppGAAAA resulted in a clear progression of the reaction, accompanied by a measurable decrease in SAM levels. These findings collectively demonstrate that Cap3MTase functions as a cap-dependent RNA methyltransferase.Figure 2Recombinant Cap3MTase possesses cap-dependent mRNA methyltransferase activity for 2′-O-methylation at the third transcribed nucleoside.A, purified Cap3MTase (2 μg) was analyzed by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The gel was stained with Coomassie Brilliant Blue. B, non-capped RNA (pppGAAAA), which has a 5′ triphosphate group, was reacted with Cap3MTase and analyzed by liquid chromatography. The chromatograms shown in black represent the analytical result of the sample without enzyme addition, while those in red represent the analytical result of the reaction mixture incubated with Cap3MTase at 37 °C for 20 min. C, chromatograms depicting the analytical results of capped RNA and the reaction products generated after incubation with various cap-dependent 2′-O-methyltransferases. The black chromatogram indicates the position of the substrate without enzyme addition, while the green, blue, red, and pink chromatograms indicate the reaction products of VP39 (Cap1 methyltransferase), TbCom1/TbMTr2 (Cap2 methyltransferase), Cap3MTase, and sequential treatment with both VP39 and TbCom1/TbMTr2, respectively. D and E, dot-maps showing the analytical results of LC–MS and LC–MS/MS corresponding to each peak in chromatogram (C), derived from capped RNA reacted with various cap-dependent 2′-O-methyltransferases. The positions of 2′-O-methyl modifications identified by LC–MS/MS analysis are indicated in bold red font with an “m” label. LC–MS, liquid chromatography–mass spectrometry; LC–MS/MS, liquid chromatography–tandem mass spectrometry. Recombinant Cap3MTase possesses cap-dependent mRNA methyltransferase activity for 2′-O-methylation at the third transcribed nucleoside.A, purified Cap3MTase (2 μg) was analyzed by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The gel was stained with Coomassie Brilliant Blue. B, non-capped RNA (pppGAAAA), which has a 5′ triphosphate group, was reacted with Cap3MTase and analyzed by liquid chromatography. The chromatograms shown in black represent the analytical result of the sample without enzyme addition, while those in red represent the analytical result of the reaction mixture incubated with Cap3MTase at 37 °C for 20 min. C, chromatograms depicting the analytical results of capped RNA and the reaction products generated after incubation with various cap-dependent 2′-O-methyltransferases. The black chromatogram indicates the position of the substrate without enzyme addition, while the green, blue, red, and pink chromatograms indicate the reaction products of VP39 (Cap1 methyltransferase), TbCom1/TbMTr2 (Cap2 methyltransferase), Cap3MTase, and sequential treatment with both VP39 and TbCom1/TbMTr2, respectively. D and E, dot-maps showing the analytical results of LC–MS and LC–MS/MS corresponding to each peak in chromatogram (C), derived from capped RNA reacted with various cap-dependent 2′-O-methyltransferases. The positions of 2′-O-methyl modifications identified by LC–MS/MS analysis are indicated in bold red font with an “m” label. LC–MS, liquid chromatography–mass spectrometry; LC–MS/MS, liquid chromatography–tandem mass spectrometry. To determine the methylation site targeted by Cap3MTase, we examined its substrate specificity in comparison to known cap-specific RNA methyltransferases (Fig. 2C). The capped oligo-mRNA substrate m7GpppGAAAA was individually incubated with VP39 (a Cap1 2′-O-methyltransferase), TbCom1/TbMTr2 (a Cap2 2′-O-methyltransferase), a mixture of both enzymes, and Cap3MTase. Liquid chromatography retention profiles revealed distinct product peaks for each reaction (Fig. 2C). Notably, the product peak derived from Cap3MTase did not coincide with those derived from Cap1, Cap2, or Cap1 + Cap2 methylation, suggesting that Cap3MTase catalyzes methyl group transfer at a novel position on the cap structure, distinct from previously characterized methylation sites. Next, the reaction products were subjected to LC–MS and LC–MS/MS analysis to determine the precise methylation site of Cap3MTase. LC–MS analysis revealed that the precursor ion m/z of the substrate m7GpppGAAAA was 2118.282 (Fig. 2D). By contrast, the precursor ion m/z values of the reaction products generated by VP39, TbCom1/TbMTr2, and Cap3MTase were all consistently 2132.295 (Fig. 2E). The reaction product obtained from the co-incubation of VP39 and TbCom1/TbMTr2 had a precursor ion m/z value of 2146.327. These results indicate that although the reaction products derived from VP39, TbCom1/TbMTr2, and Cap3MTase showed different retention times in the chromatograms (Fig. 2C), they share an identical m/z value, suggesting that they are chemically distinct compounds. Further LC–MS/MS analysis confirmed that the three isobaric compounds with identical precursor ion m/z values of 2130.2946 corresponded to distinct methylated cap structures: the product derived from VP39 was identified as Cap1, that from TbCom1/TbMTr2 as Cap2, and that from Cap3MTase as Cap3. When Cap2-GAAAA was used as a substrate and incubated with Cap3MTase for an extended period, no additional peaks other than one corresponding to Cap3-GAAAA were detected. These results suggest that Cap3MTase does not catalyze methylation beyond the Cap3 position (Fig. S1). No additional methylated products beyond Cap3-GAAAA were detected under the conditions tested, although we cannot exclude the possibility that further methylation may occur under different conditions or that enzyme activity may decrease over prolonged incubation. In addition, a minor peak observed at approximately 25 min at the 330 min time point is not consistent with the expected retention time or mass signature of additional methylated cap structures and is therefore interpreted as a degradation product or non-specific byproduct. Taken together, these findings demonstrate that Cap3MTase functions as an mRNA cap-dependent 2′-O-methyltransferase that specifically targets the third nucleoside, generating Cap3 structures. Importantly, this is the first demonstration of in vitro Cap3 activity, highlighting Cap3MTase as a unique enzyme capable of sequential cap modification beyond the canonical Cap2. Functional characterization of Cap3MTase activity To further characterize the enzymatic properties of Cap3MTase, we evaluated its activity under various biochemical conditions. The optimal temperature and pH for methyltransferase activity were determined using standard in vitro assays (Fig. 3). The results of in vitro methylation assays conducted under varying thermal conditions at pH 8.0 indicated that the optimal temperature range for Cap3MTase activity was approximately 30 °C–40 °C (Fig. 3A). Enzymatic activity was markedly reduced at temperatures above 50 °C, being nearly undetectable. Regarding the relationship between activity and pH at 37 °C, Cap3MTase showed a typical bell-shaped profile with optimal activity between pH 7.8 and 8.0 (Fig. 3B). Relative activity assays in Figure 3, A and B were performed under SAM-saturating conditions and are intended to define optimal reaction conditions rather than to estimate absolute turnover rates. The values were normalized to the maximum signal within each dataset and therefore do not necessarily represent fully saturated catalytic activity. Absolute activity measurements under defined conditions are provided in Figure 3, C and D.The specific activity of Cap3MTase for the Cap0-GAAAA substrate at pH 8.0 and 37 °C was determined to be approximately 10 units/μg-purified protein. One unit is defined as the enzymatic activity required to catalyze the transfer of 1 pmol of a methyl group per minute. The apparent Km of Cap3MTase for SAM was determined to be 172.16 ± 24.05 μm, which is considerably higher than the reported Km of VP39 for SAM at 2 μm (30) (Fig. 3C). Additional kinetic analysis using an alternative RNA substrate (GAUCGA) demonstrated that Cap3MTase retains catalytic activity on distinct sequences, although modest differences in Km and Vmax were observed compared with the GAAAA substrate. These findings suggest that RNA sequence context may influence substrate binding and catalytic efficiency, and could contribute to variations in apparent kinetic parameters, including SAM dependence. Based on the measured Vmax values and enzyme concentration, the catalytic turnover number (kcat) was calculated to be 15.97 min−1 for the GAAAA substrate and 11.90 min−1 for the GAUCGA substrate. The catalytic efficiencies (kcat/Km) were 0.0927 and 0.0677 min-1 μm−1, respectively. These results indicate that while substrate affinities are comparable, differences in catalytic turnover contribute to the observed variation in enzymatic activity between substrates.Figure 3Characterization of the 2′-O-methlytransferase activity of Cap3MTase.A, pH dependency. Reaction mixtures (10 μl) containing 50 mM Tris-HCl [pH 7.0, 7.5, 7.8, 8.0, 8.5, 9.0], 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM (at a saturating concentration), 10 pmol of Cap3MTase, and 30 μM Cap0-GAAAA substrate were incubated at 37 °C for 20 min. The products were analyzed by liquid chromatography. Enzyme activities are shown as relative values, normalized to the activity measured at pH 7.8, which corresponds to the maximal activity under these experimental conditions. B, optimal temperature. Reaction mixtures (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM (at a saturating concentration), 10 pmol of Cap3MTase, and 30 μm Cap0-GAAAA substrate were incubated at various temperatures [20 °C, 25 °C, 30 °C, 35 °C, 37 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C] for 20 min. The products were analyzed by liquid chromatography. The enzyme activity at 35 °C was set to 100%, and relative activities at other temperatures were calculated accordingly and plotted. Relative activities were normalized to the activity measured at 35 °C, representing the apparent maximal activity under these substrate-saturating conditions. Error bars represent the standard deviation from three independent experiments (n = 3) in both panels A and B; however, they are very small and may not be clearly visible. C, apparent kinetic parameters of Cap3MTase were determined. A reaction mixture (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, each concentration of SAM as specified in the graph, 10 pmol of Cap3MTase, and 30 μm of Cap0-GAAAA or Cap0-GAUCGA substrate was incubated at 37 °C for 20 min. The products were analyzed by liquid chromatography. The experiment was independently replicated four times (n = 4). The errors show the standard deviations. D, pProtein titration. Reaction mixtures (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM, 300 pmol of either Cap 0-, Cap 1- or Cap2-GAAAA substrate, and Cap3MTase as specified were incubated for 20 min at 37 °C. The amount of Cap3-GAAAA produced was quantified by liquid chromatography and plotted as a function of the concentration of Cap3MTase added to the reaction mixture. E, summary of steady-state kinetic parameters. Apparent Km, Vmax, kcat, and catalytic efficiency (kcat/Km) values were derived from the fitted curves shown in panels C and D. F, inhibition of Cap3MTase activity by S-adenosylhomocysteine (SAH). Enzymatic activity was measured in the presence of increasing concentrations of SAH (0–600 μm). A reaction mixture (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM, 10 pmol of Cap3MTase, 30 μm of Cap0-GAAAA substrate, and each concentration of SAH as specified in the graph, was incubated at 37 °C for 20 min. The products were analyzed by liquid chromatography. The experiment was independently replicated four times (n = 4). The errors show the standard deviations. DTT, dithiothreitol; SAM, S-adenosyl methionine. Characterization of the 2′-O-methlytransferase activity of Cap3MTase.A, pH dependency. Reaction mixtures (10 μl) containing 50 mM Tris-HCl [pH 7.0, 7.5, 7.8, 8.0, 8.5, 9.0], 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM (at a saturating concentration), 10 pmol of Cap3MTase, and 30 μM Cap0-GAAAA substrate were incubated at 37 °C for 20 min. The products were analyzed by liquid chromatography. Enzyme activities are shown as relative values, normalized to the activity measured at pH 7.8, which corresponds to the maximal activity under these experimental conditions. B, optimal temperature. Reaction mixtures (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM (at a saturating concentration), 10 pmol of Cap3MTase, and 30 μm Cap0-GAAAA substrate were incubated at various temperatures [20 °C, 25 °C, 30 °C, 35 °C, 37 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C] for 20 min. The products were analyzed by liquid chromatography. The enzyme activity at 35 °C was set to 100%, and relative activities at other temperatures were calculated accordingly and plotted. Relative activities were normalized to the activity measured at 35 °C, representing the apparent maximal activity under these substrate-saturating conditions. Error bars represent the standard deviation from three independent experiments (n = 3) in both panels A and B; however, they are very small and may not be clearly visible. C, apparent kinetic parameters of Cap3MTase were determined. A reaction mixture (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, each concentration of SAM as specified in the graph, 10 pmol of Cap3MTase, and 30 μm of Cap0-GAAAA or Cap0-GAUCGA substrate was incubated at 37 °C for 20 min. The products were analyzed by liquid chromatography. The experiment was independently replicated four times (n = 4). The errors show the standard deviations. D, pProtein titration. Reaction mixtures (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM, 300 pmol of either Cap 0-, Cap 1- or Cap2-GAAAA substrate, and Cap3MTase as specified were incubated for 20 min at 37 °C. The amount of Cap3-GAAAA produced was quantified by liquid chromatography and plotted as a function of the concentration of Cap3MTase added to the reaction mixture. E, summary of steady-state kinetic parameters. Apparent Km, Vmax, kcat, and catalytic efficiency (kcat/Km) values were derived from the fitted curves shown in panels C and D. F, inhibition of Cap3MTase activity by S-adenosylhomocysteine (SAH). Enzymatic activity was measured in the presence of increasing concentrations of SAH (0–600 μm). A reaction mixture (10 μl) containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM, 10 pmol of Cap3MTase, 30 μm of Cap0-GAAAA substrate, and each concentration of SAH as specified in the graph, was incubated at 37 °C for 20 min. The products were analyzed by liquid chromatography. The experiment was independently replicated four times (n = 4). The errors show the standard deviations. DTT, dithiothreitol; SAM, S-adenosyl methionine. We next examined the substrate-dependent enzymatic activity of Cap3MTase (Fig. 3D). Oligo-mRNA substrates with the sequence GAAAA and Cap0, Cap1, or Cap2 structures were incubated for 20 min at 37 °C with Cap3MTase. Across all substrates, the reaction rate increased proportionally with the amount of enzyme added, indicating a consistent dose-dependent response. Moreover, catalytic efficiency was positively correlated with degree of methylation at the cap structure: Cap1 RNA demonstrated approximately 1.8-fold higher activity than Cap0 RNA, while Cap2 RNA demonstrated 2.4-fold and 1.3-fold higher activity than Cap0 and Cap1 RNA. Our findings are consistent with previous reports demonstrating that the 2′-O-methyltransferase TbCom1/TbMTr2 exhibits higher substrate affinity for Cap1 RNA than for Cap0 RNA (9). These results suggest that higher levels of 2′-O-methylation on the substrate enhance enzymatic performance by improving substrate–enzyme affinity. To evaluate whether Cap3MTase is subject to feedback inhibition by S-adenosylhomocysteine (SAH), we measured enzymatic activity across a range of SAH concentrations (0–600 μm). As shown in Figure 3F, Cap3MTase activity decreased progressively with increasing SAH concentration. In the absence of SAH, activity was 4.39 ± 0.14 pmol, whereas at 200 μM SAH, activity decreased to 2.43 ± 0.07 pmol, corresponding to approximately 55% of the control. At 600 μm SAH, activity was further reduced to 1.18 ± 0.09 pmol (∼27% of control). Dose–response analysis yielded an apparent IC50 of approximately 74.5 μm, indicating that Cap3MTase is inhibited by SAH in a concentration-dependent manner. These results suggest that product inhibition may contribute to modulation of enzymatic activity. Synthesis, translation activity, and immunogenicity of a novel Cap3-type mRNA generated using Cap3MTase To evaluate the practical utility of Cap3MTase in mRNA engineering, we synthesized Cap3-modified mRNAs encoding LacZ reporter genes. To evaluate the feasibility of preparing Cap3-modified mRNA, we first performed enzymatic capping reactions using a 3296-nt mRNA encoding E. coli LacZ (LacZ-mRNA). The reaction conditions were according to a commercially available protocol for Cap1 formation, with the addition of TbCom1/TbMTr2 as a Cap2 methyltransferase and Cap3MTase as a Cap3 methyltransferase. Following the reaction, RNA was purified using silica membranes, and the resulting 5′-terminal fragments generated by DNAzyme cleavage were analyzed by LC–MS (Fig. 4A). The chromatograms confirmed that each RNA species used for the assay consisted of a single, desired cap structure, without contamination from other cap variants (Fig. 4B). LC–MS analysis confirmed the accurate m/z values for each capped mRNA species, indicating successful preparation of the respective cap-type mRNAs (Fig. 4B; 5′ triphosphate: 4746.541, Cap0: 5026.646, Cap1: 5040.661, Cap2: 5054.677, Cap3: 5068.693). This result simultaneously demonstrates that Cap3MTase can efficiently react with long-chain mRNAs of approximately 3300 nt as well as shorter mRNAs of approximately 650, 800, and 1200 nt (data not shown). The purified LacZ-mRNA species prepared by the capping reaction was analyzed using a Bioanalyzer, and the results showed that all samples exhibited comparable purity (Fig. 4C). No RNA degradation was observed upon use of Cap3MTase, indicating that the enzyme does not compromise RNA integrity during the capping process.Figure 4Cap structure–dependent effects on translation efficiency and innate immune activation.A, sequences and exact masses of LacZ encoded 5′ triphosphate RNA and capped RNAs (Cap0, Cap1, Cap2, Cap3) used in this study. B, LC–MS analysis of the 5′-terminal fragments generated by DNAzyme cleavage, confirming the expected m/z values for each cap structure: 5′ triphosphate (4746.519), Cap0 (5026.633), Cap1 (5040.621), Cap2 (5054.628), and Cap3 (5068.655). C, bioanalyzer electropherogram profiles of each capped RNA species, showing comparable purity and no evidence of RNA degradation across all cap types. (D and E) In vitro translation and reporter assays to evaluate the effects of cap structures. D, translation efficiency was assessed using a LacZ reporter construct. E, innate immune activation was evaluated using an NFκB reporter assay. Relative signal intensities (RLU/cell viability [AU]) are shown for each cap type. Cell viability was measured using the Cell Counting Kit-8. The black, green, blue, red, gray, and light gray bars represent Cap0, Cap1, Cap2, Cap3, 5′ triphosphate, and no RNA, respectively. Values were normalized to Cap0 (set as 1), and error bars represent the standard deviation from three independent measurements (N = 3). Asterisks indicate statistical significance as determined by Student’s t test: p < 0.05 (∗), p < 0.01 (∗∗), and p < 0.001 (∗∗∗). Notably, the signal observed in panel E reflects NFκB-mediated innate immune activation rather than translation efficiency. In particular, the signal derived from pppRNA is likely associated with activation of innate immune pathways rather than reporter translation. EM, exact mass; LC–MS, liquid chromatography–mass spectrometry; NFκB, nuclear factor κB. Cap structure–dependent effects on translation efficiency and innate immune activation.A, sequences and exact masses of LacZ encoded 5′ triphosphate RNA and capped RNAs (Cap0, Cap1, Cap2, Cap3) used in this study. B, LC–MS analysis of the 5′-terminal fragments generated by DNAzyme cleavage, confirming the expected m/z values for each cap structure: 5′ triphosphate (4746.519), Cap0 (5026.633), Cap1 (5040.621), Cap2 (5054.628), and Cap3 (5068.655). C, bioanalyzer electropherogram profiles of each capped RNA species, showing comparable purity and no evidence of RNA degradation across all cap types. (D and E) In vitro translation and reporter assays to evaluate the effects of cap structures. D, translation efficiency was assessed using a LacZ reporter construct. E, innate immune activation was evaluated using an NFκB reporter assay. Relative signal intensities (RLU/cell viability [AU]) are shown for each cap type. Cell viability was measured using the Cell Counting Kit-8. The black, green, blue, red, gray, and light gray bars represent Cap0, Cap1, Cap2, Cap3, 5′ triphosphate, and no RNA, respectively. Values were normalized to Cap0 (set as 1), and error bars represent the standard deviation from three independent measurements (N = 3). Asterisks indicate statistical significance as determined by Student’s t test: p < 0.05 (∗), p < 0.01 (∗∗), and p < 0.001 (∗∗∗). Notably, the signal observed in panel E reflects NFκB-mediated innate immune activation rather than translation efficiency. In particular, the signal derived from pppRNA is likely associated with activation of innate immune pathways rather than reporter translation. EM, exact mass; LC–MS, liquid chromatography–mass spectrometry; NFκB, nuclear factor κB. Mammalian cells possess an innate immune system that protects against invasion by exogenous pathogens, including viruses (31, 32). To evaluate the translational activity and immunogenicity of the newly synthesized Cap3-mRNAs, these mRNAs were transfected into THP1-Dual cells, and protein expression and immunogenicity were quantified using luminescence assays (Fig. 4, D and E). To evaluate translational activity using LacZ as a reporter, mRNAs bearing different cap structures were compared relative to Cap0. The translational efficiencies of Cap1-, Cap2-, and Cap3-mRNAs were higher than that of Cap0-mRNA by 1.26-fold, 1.67-fold, and 1.56-fold, respectively, with all differences being significant. However, no significant difference was detected between the translational efficiencies of Cap3-and Cap2-mRNAs. Next, we investigated the immunogenicity of mRNAs bearing different cap structures. When normalized to Cap0-mRNA (set as 1), Cap1-, Cap2-, and Cap3-mRNAs exhibited progressively lower immunogenicity, with relative values of 0.92, 0.84, and 0.78, respectively. Notably, the immunogenicity of Cap3-mRNA was significantly lower than that of Cap0 as well as Cap2-mRNA (p = 0.0267), suggesting that the Cap3 structure may further attenuate innate immune activation. Taken together, our findings highlight the potential of Cap3MTase as a versatile tool for generating functionally enhanced mRNAs suitable for therapeutic applications, including vaccines and gene therapy. Discussion The discovery and functional characterization of Cap3MTase from A. castellanii medusavirus expands our understanding of mRNA cap modification beyond the canonical Cap0–Cap2 structures commonly studied in eukaryotes and viruses. While Cap3 structures have been previously reported in kinetoplastids, the enzymatic machinery responsible for their formation has remained elusive, particularly in systems amenable to biochemical reconstitution. Our study provides the first in vitro evidence of a viral enzyme capable of catalyzing Cap3 methylation, thereby offering a new model for exploring higher-order cap mRNA methylation. Compared with the Cap1 structure, the Cap2 structure markedly decreases the recognition of mRNAs by the innate immune receptor retinoic acid–inducible gene I (RIG-I), while also enhancing mRNA stability and translational efficiency (33, 34, 35). Mechanistically, the presence of dual methylation in Cap2 structures impedes the binding of Cap1-mRNA to RIG-I because Cap2-mRNA exhibited markedly reduced affinity for RIG-I compared with Cap1-mRNA. Experimental data revealed a significantly diminished interaction between RIG-I and Cap2-mRNA, underscoring the cap-dependent nature of this recognition (34). These findings collectively indicate that compared with Cap1, the additional methylation in Cap2 RNAs further attenuates RIG-I binding. Consequently, it is reasonable to hypothesize that Cap3-mRNAs, which incorporate an additional methylation beyond Cap2, may exhibit even lower immunogenicity—a hypothesis that is supported by the experimental findings presented in this study (Fig. 4D). Human interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) plays a critical role in antiviral immune responses by selectively inhibiting the translation of viral mRNAs (36). IFIT1 selectively recognizes viral mRNAs bearing a Cap0 structure, thereby inhibiting their translation, while efficiently avoiding host mRNAs with Cap1 or Cap2 structures (37, 38). A reduction in IFIT1 binding affinity is accompanied by a corresponding increase in interaction with eukaryotic translation initiation factor 4E, which leads to enhanced translational activity of Cap1-and Cap2-mRNAs. While Cap3-mRNAs may not be endogenously present in humans, it may be inferred that their additional methylation further attenuates binding affinity to IFIT1 compared with Cap2-mRNAs. Nevertheless, our experimental data revealed no significant enhancement in translational efficiency for Cap3-mRNAs relative to Cap2-mRNAs (Fig. 4E), suggesting that the functional contribution of this modification is likely limited. A limitation of the present study is that the existence of Cap3 structures on medusavirus mRNAs during infection has not been experimentally validated. Our conclusions are therefore based on in vitro reconstitution using purified components, and do not directly demonstrate that Cap3 methylation occurs in infected cells. Future studies will be required to analyze the cap structures of viral transcripts isolated from infected host cells, for example by LC–MS-based approaches. Because medusavirus replicates in the host nucleus, it is also conceivable that Cap3MTase may access host-derived mRNAs in addition to viral transcripts. At present, the mechanisms that could confer specificity toward viral RNAs remain unclear. One possibility is that Cap3MTase is functionally coupled to the viral transcription machinery or localized to specific nuclear subdomains where viral transcription occurs, thereby preferentially targeting viral mRNAs. Alternatively, recognition of specific RNA sequence or structural features, or interactions with viral or host protein cofactors, may contribute to substrate discrimination. These possibilities remain to be investigated in future studies. The evolutionary context of Cap3MTase is also noteworthy. Cap3MTase possesses conserved features typical of 2′-O-methyltransferases, such as SAM-binding motifs and catalytic residues (Fig. 1); however, it is distinct from previously characterized enzymes in that it does not methylate the first or second transcribed nucleotides, but instead specifically targets the third nucleotide from the 5′ end. The observed sensitivity to SAH indicates that Cap3MTase is subject to product inhibition, a common feature of SAM-dependent methyltransferases. Consistent with this, an apparent IC50 in the submillimolar range was observed, suggesting moderate susceptibility to SAH inhibition. This effect may influence apparent kinetic parameters and catalytic efficiency and could become relevant in enzymatic reactions where SAH accumulates. These features raise intriguing questions about the regulation of cap maturation in medusavirus and its potential impact on viral transcript stability and host immune evasion. Medusavirus replicates within the host nucleus and encodes a suite of eukaryotic-like genes, including histone homologs and DNA polymerases (18). The presence of a functional cap methyltransferase suggests that medusavirus has adapted to exploit or mimic host RNA processing pathways, further supporting the hypothesis that the eukaryotic nucleus has a viral origin. Moreover, considering the presence of Cap3MTase identified in this study, A. castellanii medusavirus likely possesses RNAs bearing Cap3 structures. Whether the Cap3 structure produced by Cap3MTase contributes to viral fitness by enhancing translation or modulating host recognition remains an open question. The presence of Cap3 methyltransferase in giant viruses infecting Protozoa indicates that these ancestral genes related to RNA processing were horizontally transferred into Protozoa, including kinetoplastids, from these giant viruses (11). Whether these cap modifications function in known RNA maturation pathways such as trans-splicing or in yet undiscovered mechanisms remains to be elucidated. These possibilities highlight the promising directions that future research into viral RNA processing can take. Cap3MTase offers a valuable tool for mRNA engineering in a biotechnological context. Industrial mRNA synthesis for pharmaceutical applications (22, 23, 39) currently employs two major strategies for mRNA capping: 1) enzymatic capping using dedicated capping enzymes (3, 40) and 2) use of chemically synthesized cap analogs in the form of short oligonucleotide primers, enabling co-transcriptional capping during IVT—commonly referred to as chemical capping (41, 42). Both approaches are actively used in the production of capped mRNAs for therapeutic applications (43). Currently, cap analogs for Cap0 and Cap1 structures are commercially available and widely used in co-transcriptional capping methods, but no analogs are available for Cap2 or longer, more extensively methylated cap structures (Cap3). Due to their increased hydrophobicity and complex chemical properties, these higher-order cap analogs may be incompatible with standard co-transcriptional capping protocols. As a result, no established chemical capping method presently exists for synthesizing mRNAs bearing Cap2 or Cap3 structures. Although the therapeutic potential of Cap3-modified mRNAs generated using Cap3MTase remains to be fully validated, the enzyme’s high substrate affinity, broad temperature tolerance, and compatibility with long-chain mRNAs strongly support its utility in scalable mRNA production workflows. The ability to generate translationally competent and immunogenically attenuated mRNAs expands the scope of functional mRNA design, particularly for applications in vaccines and gene therapy. In summary, Cap3MTase represents a novel addition to the repertoire of cap-modifying enzymes. Its capacity to generate higher-order cap structures in vitro presents new opportunities for investigating cap-dependent regulatory mechanisms and advancing mRNA-based therapeutics. Furthermore, this study introduces a streamlined and scalable method for producing Cap3-mRNAs, which will facilitate their functional validation and accelerate the development of next-generation mRNA vaccines with improved efficacy and stability. Experimental procedures Enzyme preparation of recombinant Cap3MTase and TbCom1/TbMTr2 The open reading frames of Cap3MTase from A. castellanii medusavirus (NCBI No.: YP_010801901.1) and TbCom1/TbMTr2 from T. brucei (NCBI No.: XP_828564.1) were artificially synthesized by IDT Inc. The synthesized fragments were designed to have an 18–amino acid N-terminal peptide containing a 6 × histidine tag and a 15-mer homologous region to facilitate fusion with the plasmid vector pTrc12-6 digested with NdeI and BamHI. pTrc12-6 was derived from pTrc99A (Pharmacia) by replacing the ampicillin resistance gene with the kanamycin resistance gene. The 1.3-kb Cap3MTase gene fragment and linearized pTrc12-6 vector were fused using the In-Fusion Cloning Kit (Takara Bio Inc) to generate pTrc12-6_Cap3MTase. The expression vector pTrc12-6_Cap3MTase was transformed into E. coli BL21 cells. A 0.5-L culture of the transformant was grown at 37 °C in Difco Luria-Bertani Broth Miller medium (BD Bioscience) containing 0.05 mg/ml kanamycin (FUJI Film Wako Corp). When the optical density at 600 nm reached 0.6, isopropyl-D-thiogalactopyranoside was added to a final concentration of 0.4 mM, and the growth temperature was set to 25 °C. The total cultivation time was 24 h. The cells were harvested by centrifugation and stored at −80 °C until cell lysis. Thawed cell pellets were resuspended in 50 ml of lysis buffer [20 mM HEPES KOH pH 8.0 at 25 °C, 150 mM NaCl, 1 mM dithiothreitol (DTT), 0.1% Triton X-100]. The cell suspension was disrupted by sonication at full power, and insoluble materials were removed by centrifugation for 30 min at 15,000g. The supernatant was filtered through a 0.45-μm cellulose filter (Toyo Roshi Kaisha) and applied to a 20-mL column containing Cellufine Phosphate resin (JNC Corp). The column had been pre-equilibrated with Buffer A [20 mM HEPES KOH pH 8.0 at 25 °C, 1 mM DTT]. After applying the lysate supernatant, the column was washed with 10 volumes of Buffer A, and elution was performed with Buffer B [20 mM HEPES KOH pH 8.0 at 25 °C, 1.2 M NaCl, 1 mM DTT] using a linear gradient from 0%–100%. Fractions containing Cap3MTase were confirmed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subjected to the next purification step. The fractions were applied to a 5-mL column containing Nuvia IMAC Ni-charged resin (Bio-Rad Laboratories Inc). The column had been pre-equilibrated with Buffer A. After applying the fractions, the column was washed with 10 volumes of Buffer A, and elution was performed with Buffer C [20 mM HEPES KOH pH 8.0 at 25 °C, 0.5 M imidazole, 1 mM DTT] using a linear gradient from 0%–100%. The fractions containing Cap3MTase were pooled and applied to a 5-mL column of TOYOPEARL GigaCap Q-650S (TOSOH Corp), which had been pre-equilibrated with Buffer A. The column was washed with 10 volumes of Buffer A, and elution was performed with Buffer B using a linear gradient from 0%–100%. Cap3MTase-rich fractions were recovered and concentrated to 2 mg/ml using Amicon Ultra centrifugal filter devices (Millipore). The concentrated samples were mixed with an equal volume of 100% glycerol and stored at −25 °C. Protein concentrations were determined using Bradford dye solution (Bio-Rad Laboratories Inc), with bovine serum albumin serving as the standard. VP39, a Cap1 2′-O-methyltransferase derived from V. virus, was purchased from Takara Bio Inc. and used in the experiments. Preparation of RNA substrates Oligomer mRNA substrates were synthesized from oligonucleotide DNA fragments by in vitro transcription (IVT) using T7 RNA polymerase, as described previously (44). The template DNA fragments, synthesized by Custom Oligo DNA Synthesis Service (Thermo Fisher Scientific), consisted of a sense strand (5′-cctaatacgactcactatag-3′) and an antisense strand (5′-NNNNNctatagtgagtcgtattagg-3′), where NNNNN represents variable sequences depending on the target sequence (N indicates A, U, G, or C). For proper annealing, the two complementary DNA fragments were heated at 90 °C for 3 min and then immediately cooled at 4 °C. The transcription reactions were performed under standard IVT conditions in the presence of 7.5 mM NTPs and 15 nM DNA templates for 4 h at 37 °C. The resulting RNAs were purified through preparative ion-pair reversed-phase chromatography and desalted using a Presep C18 (octadecylsilane) solid-phase extraction device (FUJI Film Wako Corp). The amount of RNA prepared was calculated from the absorbance at 260 nm using extinction coefficients determined by the nearest-neighbor model, as described in an earlier study (45). To produce a capped RNA substrate, a reaction mixture containing 500 pmol/μl in vitro synthesized RNA, 500 pmol/μl SAM, 500 pmol/μl GTP, and 15 μg/μl Vaccinia Capping Enzyme (Takara Bio Inc) was incubated for 4 h at 37 °C. To produce RNA species with additional cap methylations, 10 μg/μl VP39 (Takara Bio Inc) was added to the above reaction to obtain Cap1-terminated RNA (m7GpppGmAAAA), and 10 μg/μl VP39 and 150 μg/μl TbCom1/TbMTr2 were added to the above reaction to obtain Cap2-terminated RNA (m7GpppGmAmAAA). The procedures following purification were performed as described above. Methyltransferase activity measurement Initial rates were determined under conditions where product formation was linear with respect to time and enzyme concentration. A standard 10-μl reaction mixture containing 50 mM Tris-HCl pH 8.0, 5 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM SAM, 10 pmol of Cap3MTase, and nuclease-free water was incubated for 20 min at 37 °C. The reaction was terminated by heating at 95 °C for 30 s and analyzed by ion-pair reversed-phase liquid chromatography on an octadecylsilane Biozen Oligo column (2.1 × 150 mm, particle size 1.7 μm; Phenomenex Inc.) connected to an LC-40D XSi chromatography system (Shimadzu Corp). The mobile phase consisted of solvent A (20 mM 1,1,1,3,3,3-hexafluoro-2-propanol [HFIP], 20 mM triethylamine-acetate in water) and solvent B (40% methanol in solvent A). A linear gradient from 0%–50% solvent B was applied over 25 min at a flow rate of 0.3 ml/min. The column temperature was maintained at 65 °C. Detection was carried out at 260 nm using an ultraviolet detector. Liquid chromatography–mass spectrometry (LC–MS) and LC–MS/MS analyses were performed using a Xevo G2-XS QTof system (Waters Corp) in negative ion mode over an m/z range of 350 to 5000 with a full scan rate of 1 Hz. The optimized electrospray ionization source parameters were as follows: capillary voltage 2.0 kV, cone voltage 45 V, source temperature 120 °C, and desolvation temperature 500 °C. The precursor ion m/z values were determined by initial MS scans, followed by targeted MS/MS analysis using manually optimized collision energies. The analytes were fragmented in the collision cell by collision-induced dissociation using voltages ranging from 15 to 50 V. Multiple MS/MS runs were conducted to ensure full sequence coverage of the oligonucleotide. Data acquisition and processing were performed using waters_connect software, and sequence confirmation was conducted using the CONFIRM Sequence application (Waters Corp). The mass tolerance was set to ±20 ppm, and fragment ion intensity thresholds were applied at 500 counts. Isotopic similarity and intensity ratio cutoffs were set at 70%. In vitro transcription and Cap3 capping of LacZ-encoding mRNA To generate a DNA template encoding E. coli LacZ for IVT, the NLuc coding region of the plasmid vector pNL1.1 [TK] (Promega) was replaced with the LacZ gene. First, pNL1.1 [TK] was linearized by PCR using Primer1 and Primer2 (refer to Supplementary file 1). Separately, the LacZ insert was amplified by PCR using Primer3 and Primer4, with E. coli genomic DNA serving as the template. The linearized vector and LacZ insert were assembled using the In-Fusion Cloning Kit, resulting in the recombinant plasmid pNL1.1 [TK]-LacZ. The IVT template DNA was subsequently prepared by PCR using a T7 promoter–containing forward Primer5 and a poly A region–containing reverse Primer6 (80 nucleotides), with pNL1.1 [TK]-LacZ serving as the template. All DNA fragments obtained during each step were purified following agarose gel electrophoresis. Gel-excised DNA was cleaned up using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. IVT was performed using T7 RNA polymerase (Takara Bio Inc.) in a 100 μl reaction containing 0.5 μg/μl DNA template, 7.5 mM NTPs, 40 mM Tris-HCl (pH 7.9), 6 mM MgCl2, 10 mM DTT, and 2 mM spermidine. The reaction was incubated at 37 °C for 4 h. The resulting RNA was purified using FastGene RNA purification columns (Nippon Genetics, Japan) and quantified using an Infinite M Plex plate reader (Tecan). Capping was performed enzymatically in the presence of 10 mM GTP and 10 mM SAM using a Cap0 capping system (Vaccinia Capping Enzyme, Takara Bio Inc) according to the manufacturer’s instructions. The reaction, carried out at 37 °C for 60 min, was supplemented with RNase inhibitor (Takara Bio Inc) to prevent RNA degradation. For Cap1, Cap2, and Cap3 modifications, simultaneous enzymatic capping reactions were performed using VP39, TbCom1/TbMTr2, and Cap3MTase, respectively. The final capped mRNA was purified using FastGene RNA purification columns and stored at −80 °C until use. The purity and integrity of each RNA sample was analyzed using a 2100 Bioanalyzer capillary gel electrophoresis system (Agilent Technologies) according to the manufacturer’s instructions. To quantify the relative abundance of individual cap structures, the target RNA was site-specifically cleaved using the specific DNAzyme, and the resulting 5′-terminal fragments were subjected to liquid chromatography analysis. The DNAzyme sequence was designed on the basis of the principles described in a previous study (46), such that it cleaves the LacZ-mRNA at nucleotide position 14 from the 5′ terminus. The 100-μl reaction mixture contained 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 15 μm DNAzyme, 500 ng/μl substrate RNA, and 1 U/μl T4 polyribonucleotide kinase (Takara Bio Inc). The reaction was incubated at 37 °C for 15 h. T4 polyribonucleotide kinase was included to remove the 3′-terminal phosphate group from the DNAzyme-cleaved RNA fragments, thereby enabling detection as a single peak in subsequent liquid chromatography analysis. The digestion products were directly subjected to liquid chromatography analysis without further purification. Nucleic acid fragments were analyzed using ion-pair reversed-phase ultra-high-performance liquid chromatography on a Biozen Oligo octadecylsilane column (2.1 × 150 mm, particle size 1.7 μm; Phenomenex Inc). The column temperature was maintained at 65 °C, and the flow rate was set to 0.3 ml/min. Mobile phase A consisted of an aqueous solution containing 1% (v/v) HFIP and 0.1% (v/v) N,N-diisopropylethylamine. Mobile phase B was composed of 65% (v/v) acetonitrile, 0.75% (v/v) HFIP, and 0.0375% (v/v) N.N-diisopropylethylamine in water. A linear gradient from 0% to 20% mobile phase B was applied over 50 min. Detection was carried out at 260 nm using an ultraviolet detector. LC–MS and LC–MS/MS analyses were performed using a Xevo G2-XS QTof system (Waters Corp), as described above. Cell culture, transfection, and reporter assays The human acute monocytic leukemia cell line THP1-Dual was sourced from InvivoGen and cultured at 37 °C with 5% CO2 following the supplier’s recommendations. Cells were plated at a density of approximately 100,000 per well in a 96-well flat-bottom plate. Transfection was carried out using Lipofectamine LTX & Plus Reagent (Invitrogen), and cells were subsequently incubated under the same conditions for 24 h before assessing LacZ expression, interferon regulatory factor activation, and cell viability. LacZ expression was measured using the Beta-Glo assay system (Promega) following the manufacturer’s protocol. Interferon regulatory factor activation was measured using the QUANTI-Luc assay (InvivoGen), while cell viability was evaluated using the Cell Counting Kit-8 (Dojindo), adhering to the manufacturer’s instructions. Absorbance and luminescence values were obtained using an Infinite M Plex plate reader (Tecan). All experiments were performed in three biological replicates (N = 3), with each conducted in triplicate. Data availability All data supporting the findings of this study are available from the corresponding author upon reasonable request. Supporting information This article contains supporting information. Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.